yahoo_financeOriginal article
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
Phase 3LIVMARLINeutral
AI Analysis
Summary
Mirum Pharmaceuticals will host an investor call to present topline results from the Phase 3 EXPAND study of LIVMARLI (maralixibat) in ultra-rare cholestatic liver diseases.
Clinical Trial Data
Phase
Phase 3
Importance:6/10
Sentiment:
0.00
Phase 3LIVMARLImaralixibatcholestatic liver diseaseinvestor call
Related Companies
Read the original article
Published by yahoo_finance on October 11, 2026 9:00 PM